THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED.
The COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, for the Laboratory of the Center for Human Immunology (CHI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to, Exiqon, 14F Gill Street, Woburn, MA 01801 to purchase the below item.

The reference number: NHLBI-CSB-(HL)-2011-347-DDC.

Product #208035, miRCURY LNA^TM microRNA, Hi-Power Labeling Kit, Hy3/Hy5 (24 rxns), quantity 40 each

The sole source determination is based on the fact that the CHI is involved in the study of Cellular and molecular characterization of the immune response in healthy NIH employees at baseline, and after immunization with the H1N1 and seasonal influenza vaccines. As part of these studies the lab using in-house miro RNA array for profiling analysis. Fluorescent label test and reference RNA samples the Hy3/Hy5 Hi-Power labeling kits are used from Exiqon. These kits will help the Government to continue the ongoing research and help figure out miroRNA expression and regulation. These kits provide a fast and simple method for fluorescent labeling of total RNA samples. All small RNAs are uniformly labeled. The labeled RNA molecules may be hybridized directly to the miR arrays, without additional microRNA enrichments or other time consuming handling steps. Exiqon is the manufacturer of this product. Therefore to keep scientific result consistency and reproducible, it is in the Government's best interest to continue service with Exiqon.

The delivery point is the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), 10 Center Drive, Building 10-Room 1C738, Bethesda, Maryland 20892.

The notice of intent is not a request for competitive proposals. Only one responsible source and no other supplies or services will satisfy agency requirements.

Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology with size standard of 500 employees; the small business set-aside does not apply to this requirement.

The acquisition is being conducted under FAR Part 13, simplified acquisition
procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-53 (August 4, 2011).

This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by September 6, 2011, 7:30am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement.

Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HL)-2011-347-DDC, may be submitted to the COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, 6701 Rockledge Drive, Suite 6042, Bethesda, Maryland 20892-7902, Attention: Deborah Coulter. Response may be submitted electronically to [email protected]. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.

 

Bid Protests Not Available